Skip to main content
logo
Frontier Biotechnologies Inc. (SHA:688221)
China flag China · Delayed Price · Currency is CNY
16.87
+0.45 (2.74%)
At close: Sep 30, 2026

Frontier Biotechnologies Financials Overview

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
378.04123.39129.47114.2584.7440.5
Revenue Growth
175.83%-4.70%13.33%34.82%109.22%-13.13%
Gross Profit
281.4738.1233.8433.1215.39-9.21
Operating Income
-32.64-260-276.9-344.22-398.56-321.33
Net Income
-21.77-268.05-201.38-328.96-356.76-260.06
Earnings Per Share
-0.06-0.72-0.54-0.88-0.98-0.72
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
906.67713.14849.51941.721,2411,480
Total Debt
419.42406.79406.56380.35278.62292.96
Net Cash (Debt)
487.25306.35442.95561.37962.381,187
Net Cash Growth
23.80%-30.84%-21.09%-41.67%-18.94%-32.01%
Net Cash Per Share
1.310.821.191.502.643.29

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
52.53-226.59-172.52-267.17-289.04-243.07
Capital Expenditures
-9.52-29.86-18.6-129.35-140.37-327.15
Free Cash Flow
43.01-256.45-191.12-396.52-429.42-570.22
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
74.45%30.89%26.14%28.99%18.16%-22.74%
Operating Margin
-8.63%-210.72%-213.87%-301.28%-470.32%-793.34%
Pretax Margin
-5.76%-217.25%-155.54%-287.93%-421.01%-654.94%
Profit Margin
-5.76%-217.25%-155.54%-287.94%-421.01%-642.07%
FCF Margin
11.38%-207.85%-147.61%-347.07%-506.74%-1407.84%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingOct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
16.7254.8028.2432.5276.29165.12